Emerging therapies for neuroendocrine tumors (NETs)—including CAM2029, CABOMETYX (cabozantinib), RYZ101 (actinium-225 DOTATATE), AlphaMedix, Paltusotine, ONC201, VMT-α-NET, Tirapazamine, CHM-2101, and others—are expected to drive growth in the NETs market over the coming years.
DelveInsight’s latest report, “Neuroendocrine Tumors – Market Insights, Epidemiology, and Market Forecast to 2034,” provides a comprehensive analysis of NETs, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Neuroendocrine Tumors market report
Some of the key facts of the Neuroendocrine Tumors Market Report:
-
In 2023, the U.S. neuroendocrine tumors (NETs) market was valued at around USD 1.53 billion and is expected to grow at a significant compound annual growth rate (CAGR) in the coming years.
-
The pharmaceutical industry has increasingly focused on radioactive isotopes, recognizing their expanding role in both the diagnosis and treatment of various cancers.
-
Treatment approaches for NETs are evolving, with endoscopic techniques gaining preference, often reducing the need for surgical interventions. Many NETs are now detected during routine procedures such as colonoscopies and endoscopies, allowing smaller tumors to be removed immediately.
-
Long-acting somatostatin analogs, particularly Novartis’ SANDOSTATIN LAR, have traditionally served as first-line therapy for NETs. While initially commercially successful, sales have declined in Europe due to the introduction of generics. No generic version has yet been approved in the U.S., primarily due to the complexity of its formulation. Teva Pharmaceuticals attempted to develop a generic but was unsuccessful, leaving opportunities for other competitors.
-
Currently, only beta-emitting radioisotopes are approved, but the industry is increasingly focusing on alpha emitters. These deliver higher linear energy transfer (LET), enhancing cellular damage and potentially overcoming resistance to existing therapies. Companies like Bristol Myers Squibb (BMS)/RayzeBio, Radiomedix/Orano Med, and Perspective Therapeutics are actively developing therapies in this area.
-
On March 5, 2025, the FDA approved Cabometyx for adults and pediatric patients aged 12 and older with previously treated, locally advanced, or metastatic well- or moderately differentiated pancreatic NETs (pNETs) and extra-pancreatic NETs (epNETs), offering a new treatment option for these rare cancers.
-
In April 2024, the FDA approved Lutathera for pediatric patients aged 12 and above with somatostatin receptor-positive gastroenteropancreatic NETs (GEP-NETs), covering foregut, midgut, and hindgut NETs. This was the first FDA approval specifically for this patient group and was based on trials demonstrating a safety profile consistent with adult patients.
-
The NETs treatment landscape is strengthened by a robust pipeline, with numerous companies advancing novel therapies. Key players include ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixis, BMS, RayzeBio, Radiomedix, Orano Med, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, and Elicera Therapeutics, among others.
-
Promising NETs therapies in development include CAM2029, CABOMETYX (cabozantinib), RYZ101 (actinium-225 DOTATATE), AlphaMedix, Paltusotine, ONC201, VMT-α-NET, Tirapazamine, CHM-2101, and additional candidates.
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
-
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
-
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
-
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
-
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
-
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
-
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
-
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
-
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Neuroendocrine Tumors Overview
Neuroendocrine Tumors (NETs) can develop in multiple regions of the body. Similar to other cancers, NETs are named according to their site of origin—for instance, a NET arising in the lungs is called a lung NET, which represents the primary tumor. When the cancer spreads to other parts of the body, it is classified as secondary or metastatic cancer. The majority of NETs originate in the gastrointestinal tract, including the stomach, small intestine, colon, pancreas, and rectum, while a smaller proportion arise in the lungs.
NETs can also originate in other organs such as the esophagus, appendix, skin, prostate, uterus, adrenal glands, and more. These tumors are categorized based on functionality and growth behavior—they may be functional (hormone-secreting) or non-functional, and can exhibit slow-growing (indolent) or aggressive behavior. The World Health Organization (WHO) has established a classification system for NETs to guide diagnosis and treatment.
Although the exact cause of NETs is not fully understood, certain risk factors have been identified, including pituitary adenomas, Von Hippel-Lindau (VHL) syndrome, and pheochromocytomas. NETs also vary widely in their growth rates; many grow very slowly and may remain stable for months or even years, meaning immediate treatment is not always required.
Neuroendocrine Tumors Market Outlook
For many patients diagnosed with neuroendocrine tumors (NETs), somatostatin analogs (SSAs) are the standard first-line therapy. These drugs help control symptoms through their hormone-suppressing (antisecretory) effects and are also believed to slow tumor growth (antiproliferative). Clinical studies have shown that patients receiving SSAs often experience longer periods without tumor progression and improved overall survival compared to placebo-treated individuals.
Beyond SSAs, newer treatment options have emerged. Everolimus, an mTOR inhibitor, represents a targeted therapy alternative, while traditional cytotoxic chemotherapy is generally ineffective for gastrointestinal NETs (GI-NETs). More recently, peptide receptor radionuclide therapy (PRRT) has been introduced for patients whose NETs do not respond to conventional treatments. Despite these advances, outcomes for patients with metastatic NETs remain challenging.
According to NCCN and ENETS guidelines, SSAs are recommended as the initial therapy when somatostatin receptor (SSTR)-based imaging is positive, the tumor is slow-growing, and tumor grade is low. For more aggressive tumors, rapidly growing lesions, or tumors with low SSTR expression, everolimus may be considered as a first-line option; otherwise, it is generally reserved for second-line treatment.
For lung NETs that progress despite SSA or everolimus therapy, additional options include chemotherapy, PRRT, nonsurgical locoregional treatments, or enrollment in clinical trials investigating experimental therapies.
Discover how the Neuroendocrine Tumors market is rising in the coming years @ https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Neuroendocrine Tumors Marketed Drugs:
-
LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis
-
SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
Neuroendocrine Tumors Emerging Drugs:
-
ITM-11 (n.c.a. 177Lu-edotreotide): ITM Solucin GmbH
-
CAM2029: Camurus
Scope of the Neuroendocrine Tumors Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Neuroendocrine Tumors Companies: ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixi, BMS, RayzeBio, Radiomedix, OranoMed, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, Elicera Therapeutics, and others
-
Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
-
Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Tumors Market Access and Reimbursement
To know what’s more in our Neuroendocrine Tumors report, visit https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Neuroendocrine Tumors Market Report:
-
Neuroendocrine Tumors market report covers a descriptive overview and comprehensive insight of the Neuroendocrine Tumors Epidemiology and Neuroendocrine Tumors market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Neuroendocrine Tumors market report provides insights into the current and emerging therapies.
-
The Neuroendocrine Tumors market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Neuroendocrine Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neuroendocrine Tumors market.
Got queries? Click here to know more about the Neuroendocrine Tumors market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Neuroendocrine Tumors Patient Share (%) Overview at a Glance
5. Neuroendocrine Tumors Market Overview at a Glance
6. Neuroendocrine Tumors Disease Background and Overview
7. Neuroendocrine Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroendocrine Tumors
9. Neuroendocrine Tumors Current Treatment and Medical Practices
10. Unmet Needs
11. Neuroendocrine Tumors Emerging Therapies
12. Neuroendocrine Tumors Market Outlook
13. Country-Wise Neuroendocrine Tumors Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Neuroendocrine Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Neuroendocrine Tumors Market Outlook 2034
Related Reports:
Neuroendocrine Tumors Pipeline Insights, DelveInsight
"Neuroendocrine Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neuroendocrine Tumors market. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Neuroendocrine Tumors treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
